Male Reproductive Organ Cancer

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Male Reproductive Organ Cancer

MalaCards integrated aliases for Male Reproductive Organ Cancer:

Name: Male Reproductive Organ Cancer 12 15 17
Genital Neoplasms, Male 44 72
Malignant Neoplasm of Male Genital Organ or Tract 12
Malignant Tumor of Male Reproductive System 12
Malignant Neoplasm of Male Genital Organs 12
Malignant Neoplasm of Male Genital Organ 12
Malignant Tumor of Male Genital Organ 12
Male Reproductive System Neoplasm 12
Tumor of Male Reproductive System 12
Neoplasm of Male Genital Organ 12
Male Genital Neoplasm 12
Male Genital Cancer 12


External Ids:

Disease Ontology 12 DOID:3856
ICD9CM 35 187.9
MeSH 44 D005834
NCIt 50 C3054 C8561
SNOMED-CT 68 93885006
UMLS 72 C0017417 C0153606

Summaries for Male Reproductive Organ Cancer

Disease Ontology : 12 A reproductive organ cancer that is manifested in the male genital system. This includes organs such as the penis and scrotum.

MalaCards based summary : Male Reproductive Organ Cancer, also known as genital neoplasms, male, is related to testicular germ cell tumor and prostate cancer. An important gene associated with Male Reproductive Organ Cancer is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Pathways in cancer and Glucose / Energy Metabolism. The drugs Neostigmine and Peripheral Nervous System Agents have been mentioned in the context of this disorder. Affiliated tissues include prostate, endothelial and nk cells, and related phenotypes are adipose tissue and neoplasm

Related Diseases for Male Reproductive Organ Cancer

Diseases related to Male Reproductive Organ Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Related Disease Score Top Affiliating Genes
1 testicular germ cell tumor 32.1 TP53 PTEN MIR145 AR
2 prostate cancer 30.9 TP53 TMPRSS2 SRD5A2 SERPINA3 PTEN PSCA
3 seminal vesicle adenocarcinoma 11.3
4 littre gland carcinoma 11.3
5 cowper gland carcinoma 11.3
6 submandibular gland cancer 10.9 TP53 KLK3
7 nodular prostate 10.9 KLK3 FOLH1 AR
8 small cell carcinoma 10.9 TP53 PTEN KLK3
9 nephrogenic adenoma 10.9 NKX3-1 KLK3 AMACR
10 bartholin's duct cyst 10.9 TP53 AR
11 urethral diverticulum 10.9 NKX3-1 KLK3 AMACR
12 penis squamous cell carcinoma 10.9
13 paratesticular adenocarcinoma 10.9
14 adenocarcinoma of the penis 10.9
15 pseudovaginal perineoscrotal hypospadias 10.8 SRD5A2 CYP17A1 AR
16 connective tissue cancer 10.8 TP53 SERPINA3 AKT1
17 hypospadias 10.8 SRD5A2 CYP17A1 AR
18 prostate sarcoma 10.8 NKX3-1 KLK3
19 rare adenocarcinoma of the breast 10.8 TP53 AKT1
20 cerebrum cancer 10.8 TP53 PTEN AKT1
21 supratentorial cancer 10.8 TP53 PTEN AKT1
22 prostate small cell carcinoma 10.8 PTEN KLK3 FOLH1 AMACR
23 atrophy of prostate 10.8 TP53 KLK3
24 pseudohermaphroditism 10.8 SRD5A2 CYP17A1 AR
25 prostatic acinar adenocarcinoma 10.8 TMPRSS2 NKX3-1 KLK3 AMACR
26 uterine anomalies 10.8 TP53 PTEN AKT1
27 pharynx squamous cell carcinoma 10.8 PTEN AKT1
28 central nervous system cancer 10.8 TP53 PTEN AKT1
29 ductal carcinoma in situ 10.8 TP53 AR AKT1
30 nervous system cancer 10.8 TP53 PTEN AKT1
31 bladder disease 10.8 TP53 KLK3 AKT1
32 pancreas disease 10.8 TP53 IGF1 AKT1
33 endocrine gland cancer 10.8 TP53 PTEN AR AKT1
34 gonadal disease 10.8 TP53 IGF1 AR AKT1
35 female reproductive system disease 10.8 TP53 PTEN AKT1
36 endometrial adenocarcinoma 10.7 TP53 PTEN AKT1
37 respiratory system cancer 10.7 TP53 PTEN GRP AKT1
38 ovarian disease 10.7 TP53 PTEN IGF1 AKT1
39 small cell cancer of the lung 10.7 TP53 PTEN GRP AKT1
40 adenoid cystic carcinoma 10.7 TP53 SERPINA3 PTEN AKT1
41 renal cell carcinoma, papillary, 1 10.7 TP53 PTEN AMACR
42 prostatic hyperplasia, benign 10.7 SRD5A2 SERPINA3 KLK3 FOLH1 CYP17A1 AR
43 gastrointestinal system cancer 10.6 TP53 PTEN AKT1
44 glioblastoma multiforme 10.6 TP53 PTEN MIR221 IGF1 AKT1
45 respiratory system disease 10.6 TP53 GRP AKT1
46 squamous cell carcinoma, head and neck 10.6 TP53 PTEN MIR221 AKT1
47 epididymis cancer 10.5
48 glans penis cancer 10.5
49 malignant tumor of undescended testis 10.5
50 prepuce cancer 10.5

Graphical network of the top 20 diseases related to Male Reproductive Organ Cancer:

Diseases related to Male Reproductive Organ Cancer

Symptoms & Phenotypes for Male Reproductive Organ Cancer

MGI Mouse Phenotypes related to Male Reproductive Organ Cancer:

# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 9.7 AKT1 AMACR AR CYP17A1 IGF1 PTEN
2 neoplasm MP:0002006 9.61 AKT1 AR IGF1 KDM4C NKX3-1 PSCA
3 reproductive system MP:0005389 9.28 AKT1 AR CYP17A1 IGF1 NKX3-1 PTEN

Drugs & Therapeutics for Male Reproductive Organ Cancer

Drugs for Male Reproductive Organ Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
2 Peripheral Nervous System Agents Phase 4
3 Autonomic Agents Phase 4
4 Neurotransmitter Agents Phase 4
5 Cholinergic Agents Phase 4
6 Cholinesterase Inhibitors Phase 4
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
Clonidine Approved Phase 3 4205-90-7 2803
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
Racepinephrine Approved Phase 3 329-65-7 838
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
14 Hormones Phase 3
15 Hormone Antagonists Phase 3
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
17 Antiemetics Phase 3
18 Gastrointestinal Agents Phase 3
19 Anti-Inflammatory Agents Phase 3
20 glucocorticoids Phase 3
21 Antineoplastic Agents, Hormonal Phase 3
22 Central Nervous System Depressants Phase 3
23 Sympathomimetics Phase 3
24 Anesthetics, Local Phase 3
25 Antihypertensive Agents Phase 3
26 Analgesics Phase 3
27 Adrenergic alpha-2 Receptor Agonists Phase 3
28 Adrenergic Agonists Phase 3
29 Adrenergic alpha-Agonists Phase 3
30 Respiratory System Agents Phase 3
31 HIV Protease Inhibitors Phase 3
protease inhibitors Phase 3
33 Adrenergic beta-Agonists Phase 3
34 Epinephryl borate Phase 3
35 Mydriatics Phase 3
36 Hypnotics and Sedatives Phase 3
37 Adrenergic Agents Phase 3
38 Anesthetics Phase 3
39 Sympatholytics Phase 3
40 Anti-Asthmatic Agents Phase 3
41 Anesthetics, General Phase 3
42 Vasoconstrictor Agents Phase 3
43 Anesthetics, Intravenous Phase 3
44 BB 1101 Phase 3
45 Bronchodilator Agents Phase 3
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
Pembrolizumab Approved Phase 2 1374853-91-4

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 The Effect of Deep Neuromuscular Blockade With Sugammadex Reversal on Shoulder Pain of Elderly Patients Undergoing Robotic Surgery: A Single-Center Double-Blinded Randomized Controlled Trial Active, not recruiting NCT03210376 Phase 4 Deep Neuromuscular Blockade (NMB);Moderate Neuromuscular Blockade (NMB);Sugammadex;Neostigmine
2 Prospective Randomized Clinical Trial to Evaluate the Use of Caudal Nerve Blocks in Adult Penile Prosthesis Surgery Recruiting NCT02740127 Phase 3 Ropivacaine;Epinephrine;Decadron;Clonidine;Propofol
3 A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer Unknown status NCT02049190 Phase 1, Phase 2 onapristone;abiraterone
4 Phase I/II Trial of Stereotactic Hypofractionated Radiotherapy of the Prostate Unknown status NCT01540994 Phase 1, Phase 2
5 Phase 2 Study for Treatment of Penis Epidermoid Carcinoma Loco-regionally Advanced or Metastatic by Association Gemcitabine-Cisplatin Completed NCT00210041 Phase 2 Gemcitabine;Cisplatin
6 An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy Completed NCT01316458 Phase 2 STI571 (Glivec®)
7 Phase IIa Dose Escalation Trial of NanoPac® Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy Completed NCT03077659 Phase 2 NanoPac®
8 A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy Completed NCT01431391 Phase 2 leuprolide acetate
9 A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer Terminated NCT00672009 Phase 2 Ixabepilone
10 An Open-label, Multi Center PET/CT Study for Investigation of Safety and Diagnostic Performance of the 68Ga Labeled PET Tracer [68Ga]RM2 in Patients With Primary Prostate Cancer Terminated NCT02483884 Phase 1, Phase 2 [68Ga]RM2
11 A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer Terminated NCT02606123 Phase 1, Phase 2 EPI-506
12 A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206 Terminated NCT02499952 Phase 2 Pembrolizumab
13 A Pilot Presurgical Study of Daratumumab (CD38 Antagonist) in Men With High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy Withdrawn NCT03035357 Phase 2 Daratumumab
14 A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies Completed NCT00749502 Phase 1 MK-4827
15 A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors Completed NCT00753415 Phase 1
16 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
17 Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults Recruiting NCT03420963 Phase 1 Cyclophosphamide;Etoposide
18 Phase I Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases Recruiting NCT03093909 Phase 1 Gemcitabine
19 Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance Recruiting NCT03162627 Phase 1 Selumetinib;Olaparib
20 A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors Recruiting NCT03435952 Phase 1 Pembrolizumab;Doxycycline
21 An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer Active, not recruiting NCT02578797 Phase 1 Apalutamide
22 A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies Withdrawn NCT02915172 Phase 1 Lenvatinib;Capecitabine
23 A Phase I Study of Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies Withdrawn NCT02812056 Phase 1 Alisertib;TAK-228
24 An Open Label Study of Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy Approved for marketing NCT01217697 Abiraterone Acetate;Prednisone\Prednisolone
25 MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness Recruiting NCT01464216
26 Development of Prostate Cancer Stereotactic Radiotherapy in Tampere Using Intra-fractional Movement Detector and Diffusion-weighted Magnetic Resonance Imaging. Recruiting NCT02319239
27 Early Non-Invasive Ventilation in Patients With Hypoxemic Respiratory Failure and Hematological Malignancies: A Prospective Randomized Controlled Trial Recruiting NCT02464696
28 Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer Recruiting NCT03344757
29 Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14) Active, not recruiting NCT02192333
30 Protection of Rectum From High Radiation Doses During Prostate Cancer Low-dose Brachytherapy Using Diluted or Non-diluted DuraSeal as a Spacer Terminated NCT01918605

Search NIH Clinical Center for Male Reproductive Organ Cancer

Cochrane evidence based reviews: genital neoplasms, male

Genetic Tests for Male Reproductive Organ Cancer

Anatomical Context for Male Reproductive Organ Cancer

MalaCards organs/tissues related to Male Reproductive Organ Cancer:

Prostate, Endothelial, Nk Cells, Kidney, Small Intestine, Testis

Publications for Male Reproductive Organ Cancer

Articles related to Male Reproductive Organ Cancer:

(show all 13)
# Title Authors PMID Year
Pretransplant Cancer in Kidney Recipients in Relation to Recurrent and De Novo Cancer Incidence Posttransplantation and Implications for Graft and Patient Survival. 38
30418430 2019
Development of Prognosis in Palliative care Study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. 38
26586684 2015
Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study. 38
26421823 2015
Development of Prognosis in Palliative care Study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. 38
24653502 2012
Obesity and familial obesity and risk of cancer. 38
21606843 2011
Development of prognosis in palliative care study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. 38
21868477 2011
Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964-2003 followed up until the end of 2006. 38
20151937 2010
Social inequality and incidence of and survival from male genital cancer in a population-based study in Denmark, 1994-2003. 38
18667299 2008
Assessment of outcomes at alternative medicine cancer clinics: a feasibility study. 38
11246933 2001
Male genital cancers. 38
9628963 1998
[Radiation injuries of the small intestine. Surgical treatment]. 38
8758520 1996
Male genital cancers. 38
8001002 1995
[Hormone therapy of male genital cancer (prostatic cancer)]. 38
2444164 1987

Variations for Male Reproductive Organ Cancer

Expression for Male Reproductive Organ Cancer

Search GEO for disease gene expression data for Male Reproductive Organ Cancer.

Pathways for Male Reproductive Organ Cancer

Pathways related to Male Reproductive Organ Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1 12.59 TP53 PTEN NKX3-1 KLK3 IGF1 AR
3 12.41 TP53 PTEN MIR221 MIR145
Show member pathways
12.37 TP53 PTEN IGF1 AKT1
Show member pathways
Show member pathways
12.27 TP53 PTEN IGF1 AKT1
Show member pathways
12.25 TP53 PTEN MIR221 IGF1
8 11.97 TP53 PTEN AR AKT1
9 11.81 TP53 PTEN IGF1
Show member pathways
11 11.78 TP53 PTEN IGF1 AKT1
12 11.74 TP53 PTEN AKT1
13 11.7 TP53 PTEN AKT1
14 11.66 PTEN KLK3 AR AKT1
15 11.57 TP53 PTEN AKT1
16 11.56 TP53 PTEN AKT1
17 11.51 KLK3 KLK2 IGF1
18 11.44 TP53 PTEN AKT1
19 11.4 TP53 MIR221 MIR145
20 11.35 TP53 PTEN AKT1
Show member pathways
11.33 NKX3-1 KLK3 AR
22 11.26 TMPRSS2 KLK3 KLK2 AR
23 11.12 PTEN IGF1 AKT1
24 10.92 TMPRSS2 NKX3-1 KLK3 KLK2 KDM4C AR
25 10.87 KLK3 KLK2 IGF1

GO Terms for Male Reproductive Organ Cancer

Biological processes related to Male Reproductive Organ Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.91 TP53 PTEN NKX3-1 MIR221 AR
2 positive regulation of cell proliferation GO:0008284 9.85 PTEN NKX3-1 KDM4C IGF1 AR AKT1
3 cell proliferation GO:0008283 9.83 TP53 PTEN IGF1 AR AKT1
4 male gonad development GO:0008584 9.79 SRD5A2 NKX3-1 AR
5 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.7 PTEN PSCA MIR221
6 negative regulation of epithelial cell proliferation GO:0050680 9.67 PTEN NKX3-1 AR
7 negative regulation of protein kinase B signaling GO:0051898 9.63 PTEN MIR145 AKT1
8 positive regulation of glycogen biosynthetic process GO:0045725 9.62 IGF1 AKT1
9 cellular response to hypoxia GO:0071456 9.62 TP53 PTEN NKX3-1 AKT1
10 zymogen activation GO:0031638 9.61 KLK3 KLK2
11 prostate gland development GO:0030850 9.6 NKX3-1 AR
12 insulin-like growth factor receptor signaling pathway GO:0048009 9.59 IGF1 AKT1
13 response to organic substance GO:0010033 9.58 PTEN AKT1
14 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.58 IGF1 AR
15 cellular response to steroid hormone stimulus GO:0071383 9.57 NKX3-1 AR
16 positive regulation of fibroblast migration GO:0010763 9.56 MIR145 AKT1
17 negative regulation of cell size GO:0045792 9.55 PTEN AKT1
18 androgen biosynthetic process GO:0006702 9.54 SRD5A2 CYP17A1
19 positive regulation of gene expression GO:0010628 9.5 TP53 PTEN NKX3-1 KDM4C IGF1 AR
20 prostate gland growth GO:0060736 9.48 PTEN AR
21 sex differentiation GO:0007548 9.43 SRD5A2 CYP17A1 AR
22 cellular response to decreased oxygen levels GO:0036294 9.4 PTEN AKT1
23 regulation of systemic arterial blood pressure GO:0003073 9.33 KLK3 KLK2 AR
24 protein kinase B signaling GO:0043491 8.92 PTEN NKX3-1 IGF1 AKT1
25 negative regulation of apoptotic process GO:0043066 10 TP53 PTEN MIR221 IGF1 AKT1

Molecular functions related to Male Reproductive Organ Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.02 TP53 PTEN KDM4C AR AKT1

Sources for Male Reproductive Organ Cancer

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....